{"id":72332,"date":"2026-08-12T11:28:38","date_gmt":"2026-08-12T03:28:38","guid":{"rendered":"https:\/\/flcube.com\/?p=72332"},"modified":"2026-08-12T11:28:38","modified_gmt":"2026-08-12T03:28:38","slug":"tempest-therapeutics-signs-strategic-partnership-with-senlang-to-advance-tpst-4003-in-vivo-car-t-candidate-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72332","title":{"rendered":"Tempest Therapeutics Signs Strategic Partnership With Senlang to Advance TPST\u20114003 In Vivo CAR\u2011T Candidate in China"},"content":{"rendered":"\n

Tempest Therapeutics, Inc.<\/strong> (NASDAQ: TPST<\/a>) announced a strategic partnership<\/strong> with Hebei Senlang Biotechnology Co., Ltd.<\/strong> (“Senlang”) to co\u2011develop Tempest’s proprietary TPST\u20114003<\/strong> product candidate. The collaboration will begin with an investigator\u2011initiated trial (“IIT”)<\/strong> in China evaluating TPST\u20114003 in approximately 10 patients<\/strong> with myasthenia gravis (“MG”)<\/strong> or multiple sclerosis (“MS”)<\/strong>. Tempest expects first patient enrollment and dosing in the fourth quarter of 2026<\/strong>.<\/p>\n\n\n\n

Deal Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Companies<\/strong><\/td>Tempest Therapeutics, Inc. (NASDAQ: TPST) \/ Hebei Senlang Biotechnology Co., Ltd.<\/td><\/tr>
Agreement Type<\/strong><\/td>Strategic development partnership<\/td><\/tr>
Asset<\/strong><\/td>TPST\u20114003 (next\u2011generation in vivo CAR\u2011T candidate)<\/td><\/tr>
Initial Study<\/strong><\/td>Investigator\u2011initiated trial (IIT) in China<\/td><\/tr>
Patient Population<\/strong><\/td>~10 patients with myasthenia gravis (MG) or multiple sclerosis (MS)<\/td><\/tr>
Timeline<\/strong><\/td>First enrollment and dosing expected Q4 2026<\/td><\/tr>
China Option<\/strong><\/td>Senlang granted exclusive option to negotiate a definitive license for TPST\u20114003 in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism<\/h2>\n\n\n\n